Assessment of In Vitro Cefiderocol Susceptibility and Comparators Against an Epidemiologically Diverse Collection of Clinical Isolates

Overview

Journal Antibiotics (Basel)

Specialty Pharmacology

Date 2022 Feb 25

PMID 35203791

Authors

Clara Balleste-Delpierre

Angel Ramirez

Laura Munoz

Christopher Longshaw

Ignasi Roca

Jordi Vila

Affiliations

Soon will be listed here.

Abstract

Cefiderocol is a catechol-substituted siderophore cephalosporin combining rapid penetration into the periplasmic space with increased stability against β-lactamases. This study provides additional data on the in vitro antimicrobial activity of cefiderocol and commercially available comparators against an epidemiologically diverse collection of clinical isolates. Antimicrobial susceptibility was tested using pre-prepared frozen 96-well microtiter plates containing twofold serial dilutions of: cefepime, ceftazidime/avibactam, imipenem/relebactam, ampicillin/sulbactam, meropenem, meropenem/vaborbactam, ciprofloxacin, minocycline, tigecycline, trimethoprim/sulfamethoxazole and colistin using the standard broth microdilution procedure in cation-adjusted Mueller-Hinton broth (CAMHB). For cefiderocol, iron-depleted CAMHB was used. A collection of 113 clinical strains of isolated from Argentina, Azerbaijan, Croatia, Greece, Italy, Morocco, Mozambique, Peru and Spain were included. The most active antimicrobial agents against our collection were colistin and cefiderocol, with 12.38% and 21.23% of non-susceptibility, respectively. A high proportion of multidrug-resistant (76.77%) and carbapenem-resistant (75.28%) isolates remained susceptible to cefiderocol, which was clearly superior to novel β-lactam/β-lactamase inhibitor combinations. Cefiderocol-resistance was higher among carbapenem-resistant isolates and isolates belonging to ST2, but could not be associated with any particular resistance mechanism or clonal lineage. Our data suggest that cefiderocol is a good alternative to treat infections caused by MDR , including carbapenem-resistant strains.

Citing Articles

Epidemiological and genomic analysis of strains from retailed raw meat.

Hamze L, Garcia-Fierro R, Drapeau A, Francois P, Endimiani A, Madec J Heliyon. 2025; 11(1):e41487.

PMID: 39831164 PMC: 11742621. DOI: 10.1016/j.heliyon.2024.e41487.

Updates on the Activity, Efficacy and Emerging Mechanisms of Resistance to Cefiderocol.

Bianco G, Boattini M, Cricca M, Diella L, Gatti M, Rossi L Curr Issues Mol Biol. 2024; 46(12):14132-14153.

PMID: 39727974 PMC: 11674395. DOI: 10.3390/cimb46120846.

Descriptive analysis of targeted carbapenemase genes and antibiotic susceptibility profiles among carbapenem-resistant tested in the Antimicrobial Resistance Laboratory Network-United States, 2017-2020.

Sabour S, Bantle K, Bhatnagar A, Huang J, Biggs A, Bodnar J Microbiol Spectr. 2024; 12(2):e0282823.

PMID: 38174931 PMC: 10845962. DOI: 10.1128/spectrum.02828-23.

Comparison of Disk Diffusion, E-Test, and Broth Microdilution Methods for Testing In Vitro Activity of Cefiderocol in .

Kolesnik-Goldmann N, Seth-Smith H, Haldimann K, Imkamp F, Roloff T, Zbinden R Antibiotics (Basel). 2023; 12(7).

PMID: 37508308 PMC: 10376138. DOI: 10.3390/antibiotics12071212.

In Vitro Activity of Cefiderocol against a Global Collection of Carbapenem-Resistant Isolates.

Seifert H, Muller C, Stefanik D, Higgins P, Wohlfarth E, Kresken M Antibiotics (Basel). 2023; 12(7).

PMID: 37508268 PMC: 10376869. DOI: 10.3390/antibiotics12071172.

References

Karlowsky J, Hackel M, Tsuji M, Yamano Y, Echols R, Sahm D . In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015. Int J Antimicrob Agents. 2018; 53(4):456-466. DOI: 10.1016/j.ijantimicag.2018.11.007. View

Novelli A, Del Giacomo P, Rossolini G, Tumbarello M . Meropenem/vaborbactam: a next generation β-lactam β-lactamase inhibitor combination. Expert Rev Anti Infect Ther. 2020; 18(7):643-655. DOI: 10.1080/14787210.2020.1756775. View

Karah N, Sundsfjord A, Towner K, Samuelsen O . Insights into the global molecular epidemiology of carbapenem non-susceptible clones of Acinetobacter baumannii. Drug Resist Updat. 2012; 15(4):237-47. DOI: 10.1016/j.drup.2012.06.001. View

Levy-Blitchtein S, Roca I, Plasencia-Rebata S, Vicente-Taboada W, Velasquez-Pomar J, Munoz L . Emergence and spread of carbapenem-resistant Acinetobacter baumannii international clones II and III in Lima, Peru. Emerg Microbes Infect. 2018; 7(1):119. PMC: 6030224. DOI: 10.1038/s41426-018-0127-9. View

Donadu M, Mazzarello V, Cappuccinelli P, Zanetti S, Madlena M, Nagy A . Relationship between the Biofilm-Forming Capacity and Antimicrobial Resistance in Clinical Isolates: Results from a Laboratory-Based In Vitro Study. Microorganisms. 2021; 9(11). PMC: 8618777. DOI: 10.3390/microorganisms9112384. View

Isler B, Doi Y, Bonomo R, Paterson D . New Treatment Options against Carbapenem-Resistant Infections. Antimicrob Agents Chemother. 2018; 63(1). PMC: 6325237. DOI: 10.1128/AAC.01110-18. View

Lashinsky J, Henig O, Pogue J, Kaye K . Minocycline for the Treatment of Multidrug and Extensively Drug-Resistant A. baumannii: A Review. Infect Dis Ther. 2017; 6(2):199-211. PMC: 5446366. DOI: 10.1007/s40121-017-0153-2. View

Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet D . Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2017; 18(3):318-327. DOI: 10.1016/S1473-3099(17)30753-3. View

Bogaerts P, Rezende de Castro R, de Mendonca R, Huang T, Denis O, Glupczynski Y . Validation of carbapenemase and extended-spectrum β-lactamase multiplex endpoint PCR assays according to ISO 15189. J Antimicrob Chemother. 2013; 68(7):1576-82. DOI: 10.1093/jac/dkt065. View

10.

Dobias J, Denervaud-Tendon V, Poirel L, Nordmann P . Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens. Eur J Clin Microbiol Infect Dis. 2017; 36(12):2319-2327. DOI: 10.1007/s10096-017-3063-z. View

11.

Trebosc V, Gartenmann S, Totzl M, Lucchini V, Schellhorn B, Pieren M . Dissecting Colistin Resistance Mechanisms in Extensively Drug-Resistant Acinetobacter baumannii Clinical Isolates. mBio. 2019; 10(4). PMC: 6635527. DOI: 10.1128/mBio.01083-19. View

12.

Golden A, Adam H, Baxter M, Walkty A, Lagace-Wiens P, Karlowsky J . In Vitro Activity of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacilli Isolated from Patients in Canadian Intensive Care Units. Diagn Microbiol Infect Dis. 2020; 97(1):115012. DOI: 10.1016/j.diagmicrobio.2020.115012. View

13.

Malik S, Kaminski M, Landman D, Quale J . Cefiderocol Resistance in Acinetobacter baumannii: Roles of β-Lactamases, Siderophore Receptors, and Penicillin Binding Protein 3. Antimicrob Agents Chemother. 2020; 64(11). PMC: 7577126. DOI: 10.1128/AAC.01221-20. View

14.

El-Lababidi R, Rizk J . Cefiderocol: A Siderophore Cephalosporin. Ann Pharmacother. 2020; 54(12):1215-1231. DOI: 10.1177/1060028020929988. View

15.

Ito A, Kohira N, Bouchillon S, West J, Rittenhouse S, Sader H . In vitro antimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria. J Antimicrob Chemother. 2015; 71(3):670-7. DOI: 10.1093/jac/dkv402. View

16.

Hackel M, Tsuji M, Yamano Y, Echols R, Karlowsky J, Sahm D . Activity of the Siderophore Cephalosporin, Cefiderocol, against Carbapenem-Nonsusceptible and Multidrug-Resistant Isolates of Gram-Negative Bacilli Collected Worldwide in 2014 to 2016. Antimicrob Agents Chemother. 2017; 62(2). PMC: 5786755. DOI: 10.1128/AAC.01968-17. View

17.

Boral B, Unaldi O, Ergin A, Durmaz R, Koseoglu Eser O . A prospective multicenter study on the evaluation of antimicrobial resistance and molecular epidemiology of multidrug-resistant Acinetobacter baumannii infections in intensive care units with clinical and environmental features. Ann Clin Microbiol Antimicrob. 2019; 18(1):19. PMC: 6607529. DOI: 10.1186/s12941-019-0319-8. View

18.

Roca I, Espinal P, Vila-Farres X, Vila J . The Acinetobacter baumannii Oxymoron: Commensal Hospital Dweller Turned Pan-Drug-Resistant Menace. Front Microbiol. 2012; 3:148. PMC: 3333477. DOI: 10.3389/fmicb.2012.00148. View

19.

Magiorakos A, Srinivasan A, Carey R, Carmeli Y, Falagas M, Giske C . Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2011; 18(3):268-81. DOI: 10.1111/j.1469-0691.2011.03570.x. View

20.

Diancourt L, Passet V, Nemec A, Dijkshoorn L, Brisse S . The population structure of Acinetobacter baumannii: expanding multiresistant clones from an ancestral susceptible genetic pool. PLoS One. 2010; 5(4):e10034. PMC: 2850921. DOI: 10.1371/journal.pone.0010034. View